Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




Oct
09
Today In Oncology
HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy
FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC
FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon Cancer
Cancer Statistics 2026: Incidence, Mortality, Survival, and Disparities in U.S. Oncology
FDA Approves First-Line Pirtobrutinib for CLL-SLL
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo